Clinical Trials Browser

NCT04149691 2024-02-07

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Phase 1 Unknown

42 enrolled

GastrointestinalGenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Carcinoma, Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Phase 1 Unknown

50 enrolled

Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT03462316 2023-04-12

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Phase 1 Unknown

20 enrolled

Sarcoma

Bone Neoplasms, Sarcoma

NCT04318964 2023-04-12

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Basal Cell, Colonic Neoplasms, Lymphoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT04556669 2021-05-27

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Phase 1 Unknown

30 enrolled

GynecologicSarcoma

Uterine Cervical Neoplasms, Sarcoma

NCT04659733 2020-12-09

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Phase 1 Unknown

36 enrolled

Sarcoma

NCT04107142 2019-09-27

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Phase 1 Unknown

10 enrolled

BreastGastrointestinalGenitourinaryHead & NeckSarcoma

Nasopharyngeal Carcinoma, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03002805 2019-08-19

CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

Phase 1 Unknown

46 enrolled

Sarcoma

NCT03076372 2018-02-27

A Study Evaluating MM-310 in Patients With Solid Tumors

Phase 1 Unknown

34 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00101309 2013-12-18

Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma

Phase 1 Unknown

10 enrolled

CNSSarcoma

Neuroblastoma, Sarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Clinical Trials

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

TAEST16001 in the Treatment of Soft Tissue Sarcoma

OLATRASTS

GEN602

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

A Study Evaluating MM-310 in Patients With Solid Tumors

Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma